271 related articles for article (PubMed ID: 15102571)
1. Nebivolol: a review.
Cockcroft J
Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
[TBL] [Abstract][Full Text] [Related]
2. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
Cockcroft J
Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
[TBL] [Abstract][Full Text] [Related]
4. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
Bakris GL; Basile JN; Giles TD; Taylor AA
Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM
J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
[TBL] [Abstract][Full Text] [Related]
6. Arterial stiffness, hypertension, and rational use of nebivolol.
Agabiti-Rosei E; Porteri E; Rizzoni D
Vasc Health Risk Manag; 2009; 5(1):353-60. PubMed ID: 19475771
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol: impact on cardiac and endothelial function and clinical utility.
Toblli JE; DiGennaro F; Giani JF; Dominici FP
Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
Agabiti Rosei E; Rizzoni D
Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Tzemos N; Lim PO; MacDonald TM
Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol: third-generation beta-blockade.
de Boer RA; Voors AA; van Veldhuisen DJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
[TBL] [Abstract][Full Text] [Related]
11. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
Zanchetti A
Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
16. [Beta blocker improves the endothelial function. Gas-forming blood vessel protection].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974334
[No Abstract] [Full Text] [Related]
17. Beta-blockers in the management of hypertension: focus on nebivolol.
Wojciechowski D; Papademetriou V
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
Moen MD; Wagstaff AJ
Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
[TBL] [Abstract][Full Text] [Related]
19. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
Weiss R
Vasc Health Risk Manag; 2006; 2(3):303-8. PubMed ID: 17326335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
